Drug intelligence / Profile preview

Quercus garryana pollen

Development stage: Unknown
Lead developer: ALK Abelló
Modality: Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Percutaneous, Subcutaneous

Overview

Quercus garryana pollen, also known as Oregon White Oak pollen or Garry oak pollen, is a natural substance derived from the Quercus garryana tree. It is a potent allergen that can trigger allergic reactions such as allergic rhinitis and asthma in sensitized individuals. When processed into allergenic extracts, it is used as a pharmaceutical agent for both diagnostic skin testing to identify specific allergies and for allergen immunotherapy (AIT) to desensitize patients and reduce the severity of their allergic symptoms.

Other names: Oregon White Oak pollenGarry oak pollen

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on Quercus garryana pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quercus garryana pollen.

Explore the full profile